Immunotherapy in lung cancer. [Review]
Citation: Journal of Surgical Oncology. 123(3):718-729, 2021 Mar.PMID: 33595888Institution: MedStar Washington Hospital CenterDepartment: Hematology/Oncology | Medicine/General Internal MedicineForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2021ISSN:- 0022-4790
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 33595888 | Available | 33595888 |
Immunotherapy has emerged as an important treatment modality throughout oncology with a particularly important role in the treatment of lung cancer. Early signals showed responses could be achieved in nonsmall cell lung cancer and small cell lung cancer and these monoclonal antibodies have become standards of care for advanced stage disease. They have also shown promise in earlier-stage disease as complements to radiation or surgery, offering the potential for durable, meaningful survival gains. Copyright (c) 2020 Wiley Periodicals LLC.
English